HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clean Air Labeling

This article was originally published in The Rose Sheet

Executive Summary

California Air Resources Board postpones review of proposed Clean Air Labeling Program to gather additional data, agency says. Labeling initiative was slated to be discussed at board's July meeting, but may be rescheduled later in the year, CARB states. Agency announced consideration of Clean Air Labeling Program as incentive for manufacturers to develop lower VOC emitting products as part of its Clean Air Plan, which was withdrawn early this year for reworking. Label would be awarded to qualifying products to inform consumers of reduced air pollution impact (1"The Rose Sheet" April 15, 2002, In Brief)...

You may also be interested in...



Clean Air labeling

California Air Resources Board will consider developing Clean Air Labeling Program as incentive for manufacturers to develop lower gas emitting products, agency says. Label would be awarded to qualifying products to inform consumers of reduced air pollution impact, CARB adds. Agency will hold public meeting April 19 in Sacramento to discuss proposal. Clean Air Plan is in development by CARB to reduce reactive gas emissions including voluntary organic compounds found in personal care products (1"The Rose Sheet" March 25, 2002, p. 3)...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel